The University of Chicago Header Logo

Connection

Daniel Arber to Leukemia, Myeloid, Acute

Back to Details
This is a "connection" page, showing publications Daniel Arber has written about Leukemia, Myeloid, Acute.
Daniel Arber
Connection Strength
10.338
Leukemia, Myeloid, Acute
  1. The Diagnostic Spectrum of Myelodysplastic Syndromes and Acute Myeloid Leukemia. Adv Anat Pathol. 2025 Jul 01; 32(4):299-306.
    View in: PubMed
    Score: 0.559
  2. Moving toward more molecular classifications of myelodysplastic syndrome and acute myeloid leukemia. Am J Hematol. 2023 03; 98(3):377-378.
    View in: PubMed
    Score: 0.483
  3. The International Consensus Classification of acute myeloid leukemia. Virchows Arch. 2023 Jan; 482(1):27-37.
    View in: PubMed
    Score: 0.477
  4. How I Diagnose Acute Leukemia of Ambiguous Lineage. Am J Clin Pathol. 2022 07 01; 158(1):27-34.
    View in: PubMed
    Score: 0.467
  5. Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach. Am J Hematol. 2022 05; 97(5):514-518.
    View in: PubMed
    Score: 0.456
  6. Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC). Am J Clin Pathol. 2020 11 04; 154(6):731-741.
    View in: PubMed
    Score: 0.417
  7. Diagnosis and treatment of mixed phenotype (T-myeloid/lymphoid) acute leukemia with novel ETV6-FGFR2 rearrangement. Blood Adv. 2020 10 13; 4(19):4924-4928.
    View in: PubMed
    Score: 0.415
  8. Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Mod Pathol. 2019 09; 32(9):1373-1385.
    View in: PubMed
    Score: 0.374
  9. Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia. Curr Treat Options Oncol. 2019 02 11; 20(2):15.
    View in: PubMed
    Score: 0.370
  10. The 2016 WHO classification of acute myeloid leukemia: What the practicing clinician needs to know. Semin Hematol. 2019 04; 56(2):90-95.
    View in: PubMed
    Score: 0.358
  11. Evaluation of Testing of Acute Leukemia Samples: Survey Result From the College of American Pathologists. Arch Pathol Lab Med. 2017 Aug; 141(8):1101-1106.
    View in: PubMed
    Score: 0.328
  12. Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis. Mod Pathol. 2017 03; 30(3):382-392.
    View in: PubMed
    Score: 0.318
  13. Significance of myelodysplastic syndrome-associated somatic variants in the evaluation of patients with pancytopenia and idiopathic cytopenias of undetermined significance. Mod Pathol. 2016 09; 29(9):996-1003.
    View in: PubMed
    Score: 0.307
  14. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. Mod Pathol. 2015 May; 28(5):706-14.
    View in: PubMed
    Score: 0.276
  15. Acute myeloid leukemia with monosomal karyotype: morphologic, immunophenotypic, and molecular findings. Am J Clin Pathol. 2014 Aug; 142(2):190-5.
    View in: PubMed
    Score: 0.270
  16. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with =30% blasts in older adults: a Bone Marrow Pathology Group study. Am J Hematol. 2014 Nov; 89(11):E193-9.
    View in: PubMed
    Score: 0.270
  17. E-cadherin is a specific marker for erythroid differentiation and has utility, in combination with CD117 and CD34, for enumerating myeloblasts in hematopoietic neoplasms. Am J Clin Pathol. 2014 May; 141(5):656-64.
    View in: PubMed
    Score: 0.265
  18. The prognostic value of CXCR4 in acute myeloid leukemia. Appl Immunohistochem Mol Morphol. 2013 Jan; 21(1):79-84.
    View in: PubMed
    Score: 0.242
  19. DNA methylation analysis of ALOX12 and GSTM1 in acute myeloid leukaemia identifies prognostically significant groups. Br J Haematol. 2012 Oct; 159(2):182-90.
    View in: PubMed
    Score: 0.236
  20. A comparison of two methods for screening CEBPA mutations in patients with acute myeloid leukemia. J Mol Diagn. 2009 Jul; 11(4):319-23.
    View in: PubMed
    Score: 0.189
  21. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood. 2009 Feb 26; 113(9):1906-8.
    View in: PubMed
    Score: 0.184
  22. Coexistence of inversion 16 and the Philadelphia chromosome in acute and chronic myeloid leukemias : report of six cases and review of literature. Am J Clin Pathol. 2006 Feb; 125(2):260-6.
    View in: PubMed
    Score: 0.150
  23. Karyotypic clonal fraction predicts adverse outcome in TP53-mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study. J Clin Pathol. 2025 Aug 18; 78(9):629-635.
    View in: PubMed
    Score: 0.145
  24. Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations. Blood Adv. 2025 Jul 08; 9(13):3370-3380.
    View in: PubMed
    Score: 0.144
  25. Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort. Blood Cancer J. 2025 May 07; 15(1):88.
    View in: PubMed
    Score: 0.142
  26. Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases. Am J Hematol. 2025 Jun; 100(6):1010-1018.
    View in: PubMed
    Score: 0.141
  27. TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management. Am J Hematol. 2025 Jun; 100 Suppl 4:88-115.
    View in: PubMed
    Score: 0.141
  28. What have we learned about TP53-mutated acute myeloid leukemia? Blood Cancer J. 2024 11 19; 14(1):202.
    View in: PubMed
    Score: 0.138
  29. Detection of NPM/MLF1 fusion in t(3;5)-positive acute myeloid leukemia and myelodysplasia. Hum Pathol. 2003 Aug; 34(8):809-13.
    View in: PubMed
    Score: 0.126
  30. Acute leukemias with complex karyotype show a similarly poor outcome independent of mixed, myeloid or lymphoblastic immunophenotype: A study from the Bone Marrow Pathology Group. Leuk Res. 2023 07; 130:107309.
    View in: PubMed
    Score: 0.124
  31. Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group. Leuk Lymphoma. 2023 05; 64(5):972-980.
    View in: PubMed
    Score: 0.123
  32. Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology Group. JCO Precis Oncol. 2023 01; 7:e2200400.
    View in: PubMed
    Score: 0.121
  33. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood. 2022 11 24; 140(21):2228-2247.
    View in: PubMed
    Score: 0.120
  34. NPM1 mutations may be associated with adverse outcome in the setting of myeloid neoplasms with complex karyotype. Leuk Res. 2022 12; 123:106965.
    View in: PubMed
    Score: 0.119
  35. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Adv. 2022 05 10; 6(9):2847-2853.
    View in: PubMed
    Score: 0.116
  36. The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. J Immunother Cancer. 2020 10; 8(2).
    View in: PubMed
    Score: 0.103
  37. Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. Am J Hematol. 2020 07; 95(7):799-808.
    View in: PubMed
    Score: 0.100
  38. Genetic Testing in the Diagnosis and Biology of Acute Leukemia. Am J Clin Pathol. 2019 08 01; 152(3):322-346.
    View in: PubMed
    Score: 0.095
  39. A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria. Mod Pathol. 2018 06; 31(6):873-880.
    View in: PubMed
    Score: 0.086
  40. Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 07; 15(7):926-957.
    View in: PubMed
    Score: 0.083
  41. The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia. Int J Lab Hematol. 2017 Apr; 39(2):129-136.
    View in: PubMed
    Score: 0.080
  42. Presence of t(8;21)(q22;q22) in myeloperoxidase-positive, myeloid surface antigen-negative acute myeloid leukemia. Am J Clin Pathol. 1997 Jan; 107(1):68-73.
    View in: PubMed
    Score: 0.080
  43. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica. 2014 May; 99(5):821-9.
    View in: PubMed
    Score: 0.065
  44. Hidden mastocytosis in acute myeloid leukemia with t(8;21)(q22;q22). Am J Clin Pathol. 2013 Oct; 140(4):525-35.
    View in: PubMed
    Score: 0.064
  45. B-cell transcription factor expression and immunoglobulin gene rearrangement frequency in acute myeloid leukemia with t(8;21)(q22;q22). Am J Clin Pathol. 2013 Sep; 140(3):355-62.
    View in: PubMed
    Score: 0.063
  46. Acute myeloid leukemia, version 2.2013. J Natl Compr Canc Netw. 2013 Sep 01; 11(9):1047-55.
    View in: PubMed
    Score: 0.063
  47. Pediatric acute myeloid leukemia as classified using 2008 WHO criteria: a single-center experience. Am J Clin Pathol. 2013 Jun; 139(6):818-25.
    View in: PubMed
    Score: 0.062
  48. NCCN Clinical Practice Guidelines Acute myeloid leukemia. J Natl Compr Canc Netw. 2012 Aug; 10(8):984-1021.
    View in: PubMed
    Score: 0.059
  49. Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia. Am J Hematol. 2012 Jan; 87(1):45-50.
    View in: PubMed
    Score: 0.056
  50. Can cytoplasmic nucleophosmin be detected by immunocytochemical staining of cell smears in acute myeloid leukemia? Haematologica. 2010 Apr; 95(4):670-3.
    View in: PubMed
    Score: 0.049
  51. Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). Leuk Res. 2010 May; 34(5):594-7.
    View in: PubMed
    Score: 0.048
  52. Immunohistochemical detection of CD10 in paraffin sections of hematopoietic neoplasms: a comparison with flow cytometry detection in 56 cases. Appl Immunohistochem Mol Morphol. 2000 Dec; 8(4):257-62.
    View in: PubMed
    Score: 0.026
  53. Untreated chronic lymphocytic leukemia concurrent with or followed by acute myelogenous leukemia or myelodysplastic syndrome. A report of five cases and review of the literature. Am J Clin Pathol. 1999 Mar; 111(3):373-8.
    View in: PubMed
    Score: 0.023
  54. The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities. Am J Clin Pathol. 1998 Feb; 109(2):211-20.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.